

Tecan publishes 2011 Annual Report and notice of its Annual General Meeting

- **Annual Report available with enhanced online functionality and as an iPad app**
- **Tecan submits compensation report to an advisory vote**
- **Significant increase in the dividend proposed, from CHF 1.00 to CHF 1.25 per share**
- **Karen Huebscher will further strengthen the Board of Directors with expertise in the life sciences**

Männedorf, Switzerland, March 28, 2012 – The Tecan Group (SIX Swiss Exchange: TECN) today announced the publication of its 2011 Annual Report in the Investor Relations section of the company's website at www.tecan.com. Tecan already published its 2011 financial results in a press release and at the Press Briefing on Annual Results and Analysts' Conference held on March 8, 2012. Today also saw the publication and dispatch of the notice of the Annual General Meeting of the Tecan Group AG. The Annual General Meeting will take place on April 18, 2012. The notice is also published on the company's website.

Annual Report published in new media

Tecan has designed attractive new information channels for presenting the 2011 Annual Report in digital form. It has considerably enhanced the functionality of the online annual report and for the first time is offering an iPad app. In addition, the financial publications will continue to be available in PDF format for download on the homepage at www.tecan.com. The company will only send out the printed version on request.

Tecan submits compensation report to an advisory vote

For the first time, Tecan will submit the compensation report to the shareholders at this year's Annual General Meeting for an advisory vote. A performance-related, fair and modern remuneration system for the Board of Directors and Management Board is a key instrument of Tecan's corporate management.

Significant increase in distribution to shareholders

On the basis of a strong balance sheet and a sustainable good business outlook, Tecan intends to increase significantly its profit distribution to shareholders. The Board of Directors will therefore propose a 25% increase in the dividend from CHF 1.00 to CHF 1.25 per share to the shareholders at the company's Annual General Meeting on April 18, 2012. The dividend will once again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax.

Election of the members of the Board of Directors

As previously announced, the Board of Directors will propose the election of Karen Huebscher as a new member at the Annual General Meeting. The Board will also propose the reelection of current members Rolf A. Classon, Heinrich Fischer, Dominique F. Baly, Dr. Oliver S. Fetzter, Gérard Vaillant and Erik Walldén. Subject to his reelection, Rolf A. Classon will remain chairman of the Board of Directors.

Dr. Lukas Braunschweiler will not be standing for reelection at the upcoming Annual General Meeting in order to focus on his role as CEO of Sonova Holding AG. Chairman Rolf A. Classon would like to thank Lukas Braunschweiler on behalf of the entire Board of Directors for his outstanding commitment and valuable contribution to the strategic development of Tecan.

New member proposed with expertise in life sciences

Karen Huebscher, born in 1963, is Managing Director of the Swiss company FibulaMedical AG, which she founded in 2012. From 1995 to 2011 she worked in various technical and managerial functions at Novartis in Switzerland and the USA. She began her career in biotechnology research. In 1997 she became manager and from 2000 to 2005 was head of global investor relations. From 2006 to 2011 Karen Huebscher worked at Novartis in the global and European management of the Vaccines & Diagnostics Division. Her main areas of activity were in corporate development, in particular the conclusion of partnership agreements in emerging markets, in strategic innovation and in marketing. Karen Huebscher has dual Swiss and British nationality. She received her PhD at the Swiss Federal Institute of Technology (ETH Zurich) in molecular biology and gained an MBA from IMD in Lausanne.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN: 1210019).



3

For further information:

Tecan Group

Martin Brändle

Head of Corporate Communications & Investor Relations

Tel. +41 (0) 44 922 84 30

Fax +41 (0) 44 922 88 89

investor@tecan.com

www.tecan.com